Optimi Health Announces Third and Final Tranche of CAD $1,000,000 Secured for Debt Financing

Rhea-AI Summary

Optimi Health Corp. has secured a non-dilutive Debt Financing Agreement and General Security Agreement for CAD$1,000,000. The loan is secured against the company's assets and will bear interest at a rate of 7.5% per annum. The loan is repayable on April 30, 2025, and the company has the option to repay it earlier with a prepayment fee. As part of the agreement, the company has granted 100,000 common share purchase warrants.

VANCOUVER, British Columbia, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and high-quality, GMP-grade natural psilocybin, is pleased to announce it has entered into a non-dilutive Debt Financing Agreement (“DFA”) and General Security Agreement (“GSA”) for total proceeds of CAD$1,000,000 (the “Loan”) from one arm’s length party (the “Lender”).

Pursuant to the DFA and the GSA, the Loan is secured against the assets of the Company and will bear interest at a rate of 7.5% per annum, payable by the Company to the Lender quarterly on the last business day of every fiscal quarter until full repayment. Upon maturity of the Loan, all outstanding principal shall be payable on April 30, 2025. The Company may repay the Loan at any time on notice to the Lender, subject to a prepayment fee. As partial consideration for the advance of the Loan from the Lender, the Company has granted a total of 100,000 common share purchase warrants (the “Warrants”), entitling the purchase of common shares in the Company. The Warrants are exercisable for three (3) years from the date of issuance, at $0.50.

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Michael Kydd
Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

Optimi Health Corp. is an end-to-end Canadian-based drug researcher and formulator licensed by Health Canada to produce and supply psychedelic substances such as 3,4-Methylenedioxymethamphetamine (“MDMA”) and natural, GMP-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe drug products throughout the world. Optimi’s products are grown at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia, making it the largest psilocybin and MDMA producer in North America.

FORWARD-LOOKING STATEMENTS

This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual information Form dated January 9, 2023, and other continuous disclosure filings available under Optimi’s profile at www.sedarplus.ca. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement.

Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

FAQ

What is the name of the company mentioned in the press release?

The company mentioned in the press release is Optimi Health Corp.

What type of company is Optimi Health?

Optimi Health is a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and high-quality, GMP-grade natural psilocybin.

What is the total amount of the loan secured by Optimi Health?

Optimi Health has secured a loan of CAD$1,000,000.

What is the interest rate on the loan?

The loan will bear interest at a rate of 7.5% per annum.

When is the loan repayable?

The loan is repayable on April 30, 2025.

Can Optimi Health repay the loan earlier?

Yes, Optimi Health has the option to repay the loan at any time on notice to the lender, subject to a prepayment fee.

What is the term of the common share purchase warrants granted by Optimi Health?

The common share purchase warrants are exercisable for three (3) years from the date of issuance.

What is the exercise price of the common share purchase warrants?

The exercise price of the common share purchase warrants is $0.50.

How can I contact Optimi Health for further information?

For interview requests or further information, you can contact Michael Kydd, the Investor Relations of Optimi Health, via email at investors@optimihealth.ca or phone at +1 (902) 880 6121. You can also visit their website at www.optimihealth.ca.